Targeting
Dry Eye Disease
&
Neuropathic Corneal Pain
OK-101 Drug Candidate
- Inflammation and pain are the most common symptoms of dry eye
- OK-101 is a novel class of chemerin receptor agonist that produces an anti-inflammatory action and reduction in neuropathic pain
- Inclusion of a lipid ‘anchor’ within the OK-101 drug molecule is designed to decrease washout due to tearing and blinking, and to enhance the ocular residence time of OK-101
Dry Eye Disease
- Dry Eye affects over 35% of the population aged 50+, with women representing approximately two-thirds of those affected
- Worldwide, ~700 M patients suffer from dry eye disease
- Several side effects and modest efficacy of currently available drugs demand new therapies to treat dry eye disease
- Huge potential for new drugs for a $5 Billion dry eye market
Rapid Clinical Development
- IND submitted Q4 2022
- Able to skip Phase 1 safety trial and go directly to Phase 2 safety and efficacy trial in dry eye disease patients
- Phase 2 trial in dry eye disease patients started May 2023
- Topline data announced in Q1 2024